Daiichi Sankyo Company, Limited D4S.F Stock
Daiichi Sankyo Company, Limited Price Chart
Daiichi Sankyo Company, Limited D4S.F Financial and Trading Overview
| Daiichi Sankyo Company, Limited stock price | 28.84 EUR |
| Previous Close | 32 EUR |
| Open | 32 EUR |
| Bid | 30.88 EUR x 50000 |
| Ask | 31.8 EUR x 50000 |
| Day's Range | 30.87 - 30.87 EUR |
| 52 Week Range | 21.06 - 34.8 EUR |
| Volume | 18 EUR |
| Avg. Volume | 38 EUR |
| Market Cap | 59.17B EUR |
| Beta (5Y Monthly) | 0.45134 |
| PE Ratio (TTM) | 154.35 |
| EPS (TTM) | 0.59 EUR |
| Forward Dividend & Yield | 0.23 (0.68%) |
| Ex-Dividend Date | September 28, 2023 |
| 1y Target Est | N/A |
D4S.F Valuation Measures
| Enterprise Value | -234544463872 EUR |
| Trailing P/E | 154.35 |
| Forward P/E | 83.432434 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.046282616 |
| Price/Book (mrq) | 0.040936653 |
| Enterprise Value/Revenue | -0.183 |
| Enterprise Value/EBITDA | -1.245 |
Trading Information
Daiichi Sankyo Company, Limited Stock Price History
| Beta (5Y Monthly) | 0.45134 |
| 52-Week Change | 58.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 34.8 EUR |
| 52 Week Low | 21.06 EUR |
| 50-Day Moving Average | 31.69 EUR |
| 200-Day Moving Average | 30.48 EUR |
D4S.F Share Statistics
| Avg. Volume (3 month) | 38 EUR |
| Avg. Daily Volume (10-Days) | 7 EUR |
| Shares Outstanding | 1.92B |
| Float | 1.92B |
| Short Ratio | N/A |
| % Held by Insiders | 1.44% |
| % Held by Institutions | 56.57% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 30 |
| Trailing Annual Dividend Yield | 93.75% |
| 5 Year Average Dividend Yield | 121.00% |
| Payout Ratio | 0.9211 |
| Last Split Factor | 3:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 8.54% |
| Operating Margin (ttm) | 9.43% |
| Gross Margin | 71.56% |
| EBITDA Margin | 14.73% |
Management Effectiveness
| Return on Assets (ttm) | 3.18% |
| Return on Equity (ttm) | 7.80% |
Income Statement
| Revenue (ttm) | 1.28T EUR |
| Revenue Per Share (ttm) | 666.9 EUR |
| Quarterly Revenue Growth (yoy) | 41.19% |
| Gross Profit (ttm) | N/A |
| EBITDA | 188.37B EUR |
| Net Income Avi to Common (ttm) | 109.19B EUR |
| Diluted EPS (ttm) | 0.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 441.92B EUR |
| Total Cash Per Share (mrq) | 230.49 EUR |
| Total Debt (mrq) | 143.09B EUR |
| Total Debt/Equity (mrq) | 9.9 EUR |
| Current Ratio (mrq) | 2.819 |
| Book Value Per Share (mrq) | 754.092 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 114.51B EUR |
| Levered Free Cash Flow (ttm) | -185855623168 EUR |
Profile of Daiichi Sankyo Company, Limited
| Country | Germany |
| State | N/A |
| City | Tokyo |
| Address | 3-5-1, Nihonbashi-honcho |
| ZIP | 103-8426 |
| Phone | 81 3 6225 1111 |
| Website | https://www.daiichisankyo.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Q&A For Daiichi Sankyo Company, Limited Stock
What is a current D4S.F stock price?
Daiichi Sankyo Company, Limited D4S.F stock price today per share is 28.84 EUR.
How to purchase Daiichi Sankyo Company, Limited stock?
You can buy D4S.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Daiichi Sankyo Company, Limited?
The stock symbol or ticker of Daiichi Sankyo Company, Limited is D4S.F.
Which industry does the Daiichi Sankyo Company, Limited company belong to?
The Daiichi Sankyo Company, Limited industry is Drug Manufacturers-General.
How many shares does Daiichi Sankyo Company, Limited have in circulation?
The max supply of Daiichi Sankyo Company, Limited shares is 1.92B.
What is Daiichi Sankyo Company, Limited Price to Earnings Ratio (PE Ratio)?
Daiichi Sankyo Company, Limited PE Ratio is 48.88136000 now.
What was Daiichi Sankyo Company, Limited earnings per share over the trailing 12 months (TTM)?
Daiichi Sankyo Company, Limited EPS is 0.59 EUR over the trailing 12 months.
Which sector does the Daiichi Sankyo Company, Limited company belong to?
The Daiichi Sankyo Company, Limited sector is Healthcare.